Methods of treatment and prevention of neurodegenerative diseases and disorders
AssigneesThomas Jefferson University, University of Medicine and Dentistry of New Jersey
InventorsYi SHI, Robert NAGELE
Life of this patent
Estimating the term…
Abstract
The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia.
Claims33
A method of treating and/or preventing a neurodegenerative disorder or disease in a subject, the method comprising identifying a subject with, or at risk of developing a neurodegenerative disease or disorder and administering to the subject in need thereof a pharmaceutical composition comprising an agent that inhibits the activity and/or expression of the Lp-PLA2 protein.
A method of treating and/or preventing a subject with or at risk of vascular dementia comprising identifying a subject with, or at risk of developing a vascular dementia and administering to a subject in need of a pharmaceutical composition comprising an agent which inhibits the activity and/or expression of Lp-PLA2 protein, wherein inhibition of the Lp-PLA2 protein reduces or stops a symptom of vascular dementia.
A method of treating and/or preventing a disease or disorder associated with an abnormal blood brain barrier in a subject, comprising identifying a subject with, or at risk of an abnormal blood brain barrier, and administering to the subject in need of a pharmaceutical composition comprising an agent which inhibits the expression and/or activity of the Lp-PLA2 protein.
A method of decreasing beta amyloid accumulation in the brain of a subject, comprising identifying a subject with, or at risk of beta amyloid accumulation in the brain and administering to the subject in need of a pharmaceutical composition comprising an agent which inhibits the expression and/or activity of Lp-PLA2 protein, wherein inhibition of the Lp-PLA2 protein reduces or stops a symptom of beta amyloid accumulation in the brain.
A method of treating and/or preventing Alzheimer's Disease in a subject in need thereof, comprising:
- (i) screening the subject for likelihood of having or developing Alzheimers Disease,
- (ii) administering to the subject a pharmaceutical composition comprising an agent which inhibits the expression and/or activity of Lp-PLA2 protein, wherein inhibition of the Lp-PLA2 protein reduced a symptom of Alzheimer's Disease, wherein the subject is identified to have an increased risk or likelihood of developing Alzheimer's Disease determined by step (i).
A method for preventing or reducing the risk of developing Alzheimer's disease, the method comprising assessing the risk of a subject developing Alzheimer's disease, wherein a clinical directs the subject to be treated with an agent which inhibits the expression and/or activity of Lp-PLA2 protein if the subject is at risk of developing Alzheimer's Disease.
Use of an agent which inhibits the expression and/or activity of Lp-PLA2 protein for the preparation of a medicant for treatment and/or prevention of a neurodegenerative disease or disorder.
Dependencies are inferred from the claim text.